SPHK1 and breast carcinoma: Consolidating previous studies using nonspecific caspase inhibitors that hint at a role of this family of proteases in SK1 proteolysis, we demonstrate that caspase‐2 is required for SK1 degradation in human breast cancer cells and that loss of caspase‐2 significantly affects sphingolipid metabolism in response to DNA damage.